TMCnet News
Research and Markets: Global Hepatitis C Therapeutics in Major Developed Markets 2013-2019DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/q3nxmh/hepatitis_c) has announced the addition of the "Global Hepatitis C Therapeutics in Major Developed Markets 2013-2019" report to their offering. The global market has the potential to grow to a value of $18.6 billion by 2019, more than tripling the 2012 market value of $5.8 billion Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape. The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales. However, these products are very poorly tolerated and only moderately efficacious. The approval of the DAA Sovaldi in December 2013 changed this, with a complete viral clearance being achieved in close to 100% of patients and a much improved adverse event profile compared to previous standards of therapy. In patients with genotype 2 and 3 hepatitis C, Sovaldi does not need to be administered with pegylated interferon. A number of products in the late-stage pipeline, which promise to be even more efficacious and safe are anticipated to enter the market over the forecast period, includingseveral interferon-free therapies for genotype 1-infected patients. As a result of this, as well as an overall increase in the treated population, the authors believe the global market has the potential to grow to a value of $18.6 billion by 2019, more than tripling the 2012 market value of $5.8 billion. Scope
Key Topics Covered: 1 Tables & Figures 2 Introduction
3 Marketed Products
4 Developmental Pipeline
5 Market Forecast to 2019 6 Drivers and Barriers 7 Licensing and Co-development deals 8 Appendix For more information visit http://www.researchandmarkets.com/research/q3nxmh/hepatitis_c
|